A number of candidate vaccines are still under development: Among them, the NCT02287428 trial, a cohort of eight patients with high-risk MGMT unmethylated GBM, received standard of care treatments and the peptide-based vaccine containing up to 20 long peptides, each containing 3–5 personalized neoantigenic peptides. This evidence concerns the gene MGMT and glioblastoma.